Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Furio Pacini Clear advanced filters

  • Recombinant human TSH (rhTSH) is now available for use in patients with thyroid cancer. As discussed in this article, it is used as preparation before radioiodine-mediated thyroid-remnant ablation and to stimulate serum thyroglobulin levels. Using rhTSH avoids many of the unwanted effects caused by withdrawal of levothyroxine therapy.

    • Martin Schlumberger
    • Marcel Ricard
    • Furio Pacini
    Reviews
    Nature Clinical Practice Endocrinology & Metabolism
    Volume: 3, P: 641-650

  • BRAF mutation detection in cytological samples from thyroid nodules increases the sensitivity of cytology for the diagnosis of thyroid cancer and is believed to be a marker of aggressive disease. Lee et al. demonstrate high-sensitivity detection of the BRAF mutation with a new assay technique, but disprove the association with tumour aggressiveness.

    • Furio Pacini
    News & Views
    Nature Reviews Endocrinology
    Volume: 8, P: 390-391

  • Several studies have demonstrated that reactivation of telomerase in the presence of short telomeres is one of the most common features of human cancers. This Review focuses on the alterations of the telomerase complex that are associated with cancers of the endocrine system, particularly the possible diagnostic, prognostic and therapeutic applications of telomerase.

    • Furio Pacini
    • Silvia Cantara
    • Stefania Marchisotta
    Reviews
    Nature Reviews Endocrinology
    Volume: 7, P: 420-430

  • Cancers derived from follicular thyroid cells, which produce the iodine-containing thyroid hormones, have an excellent prognosis. In this Primer, Dralle et al. describe the advances in the molecular characterization of the tumours and the current state-of-the-art in diagnosis and management.

    • Henning Dralle
    • Andreas Machens
    • Steven I. Sherman
    Reviews
    Nature Reviews Disease Primers
    Volume: 1, P: 1-18